Grant of Interim Extension of the Term of U.S. Patent No. 4,650,787; Vapreotide Acetate, 61433-61434 [05-21191]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 204 / Monday, October 24, 2005 / Notices
Avenue, NW., Washington, DC 20230;
telephone: (202) 482–4162 or (202) 482–
4406, respectively.
SUPPLEMENTARY INFORMATION:
exist for the period July 1, 2003, through
June 30, 2004:
Background
Vita Food Factory
(1989) Ltd. .................
Thai Pineapple Canning
Industry Corp., Ltd. ...
61433
On August 8, 2005, the Department
published in the Federal Register the
preliminary results of the administrative
review of the antidumping duty order
on canned pineapple fruit from
Thailand. See Canned Pineapple Fruit
From Thailand: Preliminary Results of
Antidumping Duty Administrative
Review, 70 FR 45651 (August 8, 2005)
(Preliminary Results). No interested
parties filed case briefs in response to
the Department’s invitation to comment
on the Preliminary Results.
Scope of the Order
The product covered by the order is
canned pineapple fruit, defined as
pineapple processed and/or prepared
into various product forms, including
rings, pieces, chunks, tidbits, and
crushed pineapple, that is packed and
cooked in metal cans with either
pineapple juice or sugar syrup added.
Imports of canned pineapple fruit are
currently classifiable under subheadings
2008.20.0010 and 2008.20.0090 of the
Harmonized Tariff Schedule of the
United States (HTSUS). HTSUS
2008.20.0010 covers canned pineapple
fruit packed in a sugar–based syrup;
HTSUS 2008.20.0090 covers canned
pineapple fruit packed without added
sugar (i.e., juice–packed). The HTSUS
subheadings are provided for
convenience and customs purposes. The
written description of the merchandise
covered by this order is dispositive.
Partial Final Rescission of Review
As stated in the preliminary results of
this review, the Department confirmed
that Prachuab Fruit Canning Co., Ltd.
(PRAFT) made no shipments of subject
merchandise during the POR. Therefore,
consistent with the Department’s
preliminary results of this review, and
in accordance with 19 CFR
§ 351.213(d)(3), we are rescinding the
instant review with respect to PRAFT.
Analysis of Comments Received
As noted above, we received no
comments on the preliminary results of
review. In these final results, we have
made no changes to the weighted–
average dumping margins calculated for
TPC and Vita in the preliminary results
of this administrative review.
Final Results of Review
We determine that the following
weighted–average percentage margins
VerDate Aug<31>2005
15:19 Oct 21, 2005
Jkt 208001
Manufacturer/Exporter
manufacturer is a firm covered in this or
any previous review conducted by the
Department, the cash deposit rate will
Margin (percent)
be the ‘‘all others’’ rate, which is 24.64
percent. These deposit requirements
shall remain in effect until publication
9.12
of the final results of the next
51.16 administrative review.
Assessment
The Department will determine, and
CBP shall assess, antidumping duties on
all appropriate entries. In accordance
with 19 CFR § 351.212(b)(1), we
calculated importer–specific assessment
rates for Vita’s subject merchandise.
Since Vita did not report the entered
value for its sales, we calculated per–
unit assessment rates for its
merchandise by aggregating the
dumping margins calculated for all U.S.
sales to each importer and dividing this
amount by the total quantity of those
sales. To determine whether the per–
unit duty assessment rates were de
minimis (i.e., less than 0.50 percent ad
valorem), in accordance with the
requirement set forth in 19 CFR
§ 351.106(c)(2), we calculated importer–
specific ad valorem ratios based on
export prices. Where the importer–
specific assessment rate is above de
minimis, we will instruct CBP to assess
the importer–specific rate uniformly on
all entries made during the POR. For
TPC, the respondent receiving a
dumping margin based upon adverse
facts available (AFA), we will instruct
CBP to liquidate entries according to the
AFA ad valorem rate. The Department
will issue appropriate assessment
instructions directly to CBP within 15
days of publication of these final results
of review.
Cash Deposit Requirements
The following deposit requirements
will be effective for all shipments of
canned pineapple fruit from Thailand
entered, or withdrawn from warehouse,
for consumption on or after the date of
publication of these final results of
review, as provided by section 751(a)(1)
of the Act: (1) the cash deposit rates for
Vita and TPC will be the rates shown
above; (2) for previously reviewed or
investigated companies not listed above,
the cash deposit rate will continue to be
the company–specific rate published for
the most recent period; (3) if the
exporter is not a firm covered in this
review, a prior review, or the less–thanfair–value investigation, but the
manufacturer is, the cash deposit rate
will be the rate established for the most
recent period for the manufacturer of
the subject merchandise; and (4) if
neither the exporter nor the
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
Reimbursement of Duties
This notice also serves as a final
reminder to importers of their
responsibility under 19 CFR
§ 351.402(f)(2) to file a certificate
regarding the reimbursement of
antidumping duties prior to liquidation
of the relevant entries during this
review period. Failure to comply with
this requirement could result in the
Secretary’s presumption that
reimbursement of the antidumping
duties occurred and the subsequent
assessment of double antidumping
duties.
Administrative Protective Orders
This notice also serves as a reminder
to parties subject to administrative
protective orders (APOs) of their
responsibility concerning the return or
destruction of proprietary information
disclosed under APO in accordance
with 19 CFR § 351.305. Timely written
notification of the return/destruction of
APO materials or conversion to judicial
protective order is hereby requested.
Failure to comply with the regulations
and terms of an APO is a violation that
is subject to sanction.
We are issuing and publishing these
results and notice in accordance with
sections 751(a)(1) and 771(i)(1) of the
Tariff Act of 1930, as amended.
Dated: October 17, 2005.
Joseph A. Spetrini,
Acting Assistant Secretary for Import
Administration.
[FR Doc. E5–5863 Filed 10–21–05; 8:45 am]
Billing Code: 3510–DS–S
DEPARTMENT OF COMMERCE
[Docket No. 2005–P–071]
Patent and Trademark Office
Grant of Interim Extension of the Term
of U.S. Patent No. 4,650,787;
Vapreotide Acetate
United States Patent and
Trademark Office.
ACTION: Notice of interim patent term
extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
E:\FR\FM\24OCN1.SGM
24OCN1
61434
Federal Register / Vol. 70, No. 204 / Monday, October 24, 2005 / Notices
a one-year interim extension of the term
of U.S. Patent No. 4,650,787.
FOR FURTHER INFORMATION CONTACT:
Karin Ferriter by telephone at (571)
272–7744; by mail marked to her
attention and addressed to Mail Stop
Patent Ext., Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7744, or by e-mail to
Karin.Ferriter@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On April 7, 2005, H3 Pharma, Inc., an
agent of the Administrators of the
Tulane Educational Fund of New
Orleans, Louisiana, the patent owner,
timely filed an application under 35
U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 4,650,787.
The patent claims the active ingredient
vapreotide acetate in the human drug
product Sanvar, and a method of use
of said product. The application
indicates that a New Drug Application
for Sanvar (vapreotide acetate) has
been filed and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Since the
regulatory review period extended
beyond the expiration date of the patent
April 25, 2005, interim extension of the
patent term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,650,787 is granted for a period of one
year from the expiration date of the
patent, i.e., until April 25, 2006.
SUPPLEMENTARY INFORMATION:
Dated: October 17, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. 05–21191 Filed 10–21–05; 8:45 am]
BILLING CODE 3510–16–P
VerDate Aug<31>2005
15:19 Oct 21, 2005
Jkt 208001
COMMODITY FUTURES TRADING
COMMISSION
Sunshine Act Meeting
AGENCY HOLDING THE MEETING:
Commodity Futures Trading
Commission
FEDERAL REGISTER CITATION OF PREVIOUS
ANNOUNCEMENT: 70 FR 194.
PREVIOUSLY ANNOUNCED TIME AND DATE OF
THE MEETING: 11 a.m., Wednesday,
October 26, 2005.
The Rule
Enforcement Review has been moved to
Friday, October 28, 2005, at 11:45 a.m.
CONTACT PERSON FOR MORE INFORMATION:
Jean A. Webb, (202) 418–5100.
CHANGES IN THE MEETING:
Jean A. Webb,
Secretary of the Commission.
[FR Doc. 05–21319 Filed 10–20–05; 2:24 pm]
BILLING CODE 6351–01–M
DEPARTMENT OF DEFENSE
Office of the Secretary
TRICARE; Civilian Health and Medical
Program of the Uniformed Services
(CHAMPUS); Fiscal Year 2006
Diagnosis Related Group (DRG)
Updates
Office of the Secretary, DoD.
Notice of DRG revised rates.
AGENCY:
ACTION:
SUMMARY: This notice describes the
changes made to the TRICARE DRGbased payment system in order to
conform to changes made to the
Medicare Prospective Payment System
(PPS). It also provides the updated fixed
loss cost outlier threshold, cost-tocharge ratios and the Internet address
for accessing the updated adjusted
standardized amount and DRG relative
weights to be used for FY 2006 under
the TRICARE DRG-based payment
system.
The rates, weights and
Medicare PPS changes which affect the
TRICARE DRG-based payment system
contained in this notice are effective for
admissions occurring on or after
October 1, 2005.
ADDRESSES: TRICARE Management
Activity (TMA), Medical Benefits and
Reimbursement Systems, 16401 East
Centretech Parkway, Aurora, CO 80011–
9066.
FOR FURTHER INFORMATION CONTACT:
Marty Maxey, Medical Benefits and
Reimbursement Systems, TMA,
telephone (303) 676–3627. Questions
regarding payment of specific claims
under the TRICARE DRG-based
EFFECTIVE DATES:
PO 00000
Frm 00012
Fmt 4703
Sfmt 4703
payment system should be addressed to
the appropriate contractor.
SUPPLEMENTARY INFORMATION: The final
rule published on September 1, 1987 (52
FR 32992) set forth the basic procedures
used under the CHAMPUS DRG-based
payment system. This was subsequently
amended by final rules published
August 31, 1988 (53 FR 33461), October
21, 1988 (53 FR 41331), December 16,
1988 (53 FR 50515), May 30, 1990 (55
FR 21863), October 22, 1990 (55 FR
42560), and September 10, 1998 (63 FR
48439). An explicit tenet of these final
rules, and one based on the statute
authorizing the use of DRGs by
TRICARE, is that the TRICARE DRGbased payment system is modeled on
the Medicare PPS, and that, whenever
practicable, the TRICARE system will
follow the same rules that apply to the
Medicare PPS. The Centers for Medicare
and Medicaid Services (CMS) publishes
these changes annually in the Federal
Register and discusses in detail the
impact of the changes. In addition, this
notice updates the rates and weights in
accordance with our previous final
rules. The actual changes we are
making, along with a description of
their relationship to the Medicare PPS,
are detailed below.
I. Medicare PPS Changes Which Affect
the TRICARE DRG-Based Payment
System
Following is a discussion of the
changes CMS has made to the Medicare
PPS that affect the TRICARE DRG-based
payment system.
A. DRG Classifications
Under both the Medicare PPS and the
TRICARE DRG-based payment system,
cases are classified into the appropriate
DRG by a Grouper program. The
Grouper classifies each case into a DRG
on the basis of the diagnosis and
procedure codes and demographic
information (that is, sex, age, and
discharge status). The Grouper used for
the TRICARE DRG-based payment
system is the same as the current
Medicare Grouper with two
modifications. The TRICARE system has
replaced Medicare DRG 435 with two
age-based DRGs (900 and 901), and has
implemented thirty-four (34) neonatal
DRGs in place of Medicare DRGs 385
through 390. For admissions occurring
on or after October 1, 2001, DRG 435 has
been replaced by DRG 523. The
TRICARE system has replaced DRG 523
with the two age-based DRGs (900 and
901). For admissions occurring on or
after October 1, 1995, the CHAMPUS
grouper hierarchy logic was changed so
the age split (age <29 days) and
assignments to MDC 15 occur before
E:\FR\FM\24OCN1.SGM
24OCN1
]]>Agencies
[Federal Register Volume 70, Number 204 (Monday, October 24, 2005)]
[Notices]
[Pages 61433-61434]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-21191]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
[Docket No. 2005-P-071]
Patent and Trademark Office
Grant of Interim Extension of the Term of U.S. Patent No.
4,650,787; Vapreotide Acetate
AGENCY: United States Patent and Trademark Office.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
[[Page 61434]]
a one-year interim extension of the term of U.S. Patent No. 4,650,787.
FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at (571)
272-7744; by mail marked to her attention and addressed to Mail Stop
Patent Ext., Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450; by fax marked to her attention at (571) 273-7744, or by e-
mail to Karin.Ferriter@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On April 7, 2005, H3 Pharma, Inc., an agent of the Administrators
of the Tulane Educational Fund of New Orleans, Louisiana, the patent
owner, timely filed an application under 35 U.S.C. 156(d)(5) for an
interim extension of the term of U.S. Patent No. 4,650,787. The patent
claims the active ingredient vapreotide acetate in the human drug
product Sanvar[reg], and a method of use of said product. The
application indicates that a New Drug Application for Sanvar[reg]
(vapreotide acetate) has been filed and is currently undergoing
regulatory review before the Food and Drug Administration for
permission to market or use the product commercially.
Review of the application indicates that except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Since the regulatory review period extended beyond
the expiration date of the patent April 25, 2005, interim extension of
the patent term under 35 U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,650,787 is granted for a period of one year from the
expiration date of the patent, i.e., until April 25, 2006.
Dated: October 17, 2005.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. 05-21191 Filed 10-21-05; 8:45 am]
BILLING CODE 3510-16-P
